Factors associated with hepatitis C and HIV testing uptake among men who inject image and performance enhancing drugs.
暂无分享,去创建一个
J. McVeigh | V. Hope | Josie Smith | C. Edmundson | E. Heinsbroek | R. Glass | M. Whitfield | G. Morgan | D. Acreman | Joseph Kean | J. Campbell | Emma Begley
[1] B. Larance,et al. Health Care Engagement Behaviors of Men who Use Performance- and Image-Enhancing Drugs in Australia , 2019, Substance abuse.
[2] S. Fraser,et al. Is another relationship possible? Connoisseurship and the doctor-patient relationship for men who consume performance and image-enhancing drugs. , 2019, Social science & medicine.
[3] Steven Keen,et al. Support for people who use Anabolic Androgenic Steroids: A Systematic Scoping Review into what they want and what they access , 2019, BMC Public Health.
[4] V. Hope,et al. Infections and risk among people who use image and performance enhancing drugs , 2019, Human Enhancement Drugs.
[5] W. Waring,et al. Pharmacological effects and safety monitoring of anabolic androgenic steroid use: differing perceptions between users and healthcare professionals , 2019, Therapeutic advances in drug safety.
[6] L. Westlye,et al. Cognitive Performance and Structural Brain Correlates in Long-Term Anabolic-Androgenic Steroid Exposed and Nonexposed Weightlifters , 2019, Neuropsychology.
[7] R. Ralphs,et al. Polydrug use and polydrug markets amongst image and performance enhancing drug users: Implications for harm reduction interventions and drug policy. , 2019, The International journal on drug policy.
[8] H. Wand,et al. Health risk and health seeking behaviours among people who inject performance and image enhancing drugs who access needle syringe programs in Australia. , 2018, Drug and alcohol review.
[9] J. McVeigh,et al. Identifying a typology of men who use anabolic androgenic steroids (AAS). , 2018, The International journal on drug policy.
[10] J. Parry,et al. Low levels of hepatitis C diagnosis and testing uptake among people who inject image and performance enhancing drugs in England and Wales, 2012-15. , 2017, Drug and alcohol dependence.
[11] J. Copeland,et al. Risk and blood‐borne virus testing among men who inject image and performance enhancing drugs, Sydney, Australia , 2017, Drug and alcohol review.
[12] J. McVeigh,et al. Anabolic steroids in the UK: an increasing issue for public health , 2017 .
[13] H. Pope,et al. Polypharmacy, Infectious Diseases, Sexual Behavior, and Psychophysical Health Among Anabolic Steroid-Using Homosexual and Heterosexual Gym Patrons in San Francisco's Castro District , 2017, Substance use & misuse.
[14] T. Kaufmann,et al. Brain connectivity aberrations in anabolic-androgenic steroid users , 2016, NeuroImage: Clinical.
[15] F. McKay,et al. Do performance and image enhancing drug users in regional Queensland experience difficulty accessing health services? , 2016, Drug and alcohol review.
[16] J. McVeigh,et al. Access to needle and syringe programs by people who inject image and performance enhancing drugs. , 2016, The International journal on drug policy.
[17] Ross J. Harris,et al. Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance Enhancing Drugs in England and Wales: Results From Cross-Sectional Prevalence Surveys, 1992–2013 , 2016, Journal of acquired immune deficiency syndromes.
[18] I. van Beek,et al. Performance and image enhancing drug injectors' access to needle syringe programs: Responding to a public policy dilemma. , 2015, The International journal on drug policy.
[19] T. Hildebrandt,et al. Healthcare professionals' stigmatization of men with anabolic androgenic steroid use and eating disorders. , 2015, Body image.
[20] J. McVeigh,et al. Polypharmacy among anabolic-androgenic steroid users: a descriptive metasynthesis , 2015, Substance Abuse Treatment, Prevention, and Policy.
[21] J. McVeigh,et al. Variability and dilemmas in harm reduction for anabolic steroid users in the UK: a multi-area interview study , 2014, Harm Reduction Journal.
[22] R. Wood,et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. , 2014, Endocrine reviews.
[23] F. McKay,et al. Steroid users and the unique challenge they pose to needle and syringe program workers. , 2014, Drug and alcohol review.
[24] S. Zeuzem,et al. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. , 2014, Journal of hepatology.
[25] J. Parry,et al. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study , 2013, BMJ Open.
[26] H. Wand,et al. Are people who inject performance and image-enhancing drugs an increasing population of Needle and Syringe Program attendees? , 2013, Drug and alcohol review.
[27] Tonya Dodge,et al. The use of anabolic androgenic steroids and polypharmacy: a review of the literature. , 2011, Drug and alcohol dependence.
[28] R. Coomber,et al. Injecting drug users: a stigmatised and stigmatising population. , 2009, The International journal on drug policy.
[29] C. Day,et al. Blood-borne virus prevalence and risk among steroid injectors: results from the Australian Needle and Syringe Program Survey. , 2008, Drug and alcohol review.
[30] J. Elford,et al. Use of anabolic steroids and associated health risks among gay men attending London gyms. , 2002, Addiction.
[31] J. Parry,et al. The risk of infection with HIV and hepatitis B in individuals who inject steroids in England and Wales , 1998, Epidemiology and Infection.
[32] J. de Irala,et al. Reliability of self-reported human immunodeficiency virus risk behaviors in a residential drug treatment population. , 1996, American journal of epidemiology.
[33] D. Vlahov,et al. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. , 1993, Addiction.